Harrow Health(HROW) - 2023 Q4 - Earnings Call Presentation

"VEVYE represents a breakthrough in dry eye treatment. Patients with sensitive eyes, often susceptible to side effects from prescription eyedrops, finally have a solution. VEVYE is the first topical immunomodulator that hasn't had any side effects of stinging, while also having the highest concentration of cyclosporine on the market. Unsurprisingly, the feedback from patients has been tremendous." "VEVYE's performance has been outstanding in terms of accessibility, especially for a new entrant to the pharma ...